Next Unicorns: Developing drugs to extend dog lifespans with Loyal CEO Celine Halioua | E1799

In this episode, Jason Calacanis is joined by Loyal CEO, Celine Halioua. They discuss her journey into life extension, her focus on dogs, and the drugs Loyal is developing. The conversation delves into the science behind the drugs, the impact of selective breeding, and environmental factors in drug development. They also touch on the challenges of commercialization, Halioua's experience as a solo founder, and the importance of staying intellectually curious.

Speakers

AI Chat

Jason Calacanis

Host • 48%

Unidentified

Celine Halioua

Guest • 50%

Partners

Chapters

0:00	Loyal CEO Celine Halioua joins Jason
1:43	The human dream of achieving life extension
4:37	Celine’s background
8:48	Fount - Get $500 off
10:19	Why Celine decided to start with a focus on dogs
16:43	Wegovy, Ozempic, and the category of drugs that Loyal is developing
20:44	Breaking down how the drugs work and the consequences of selective breeding
24:21	LinkedIn Jobs - Post your first job for free
25:36	Stem cell therapy and the placebo effect
33:29	Environmental factors to consider in drug development
37:05	The path to commercialization
39:27	Catalog - Get $1200 off right now
40:56	Staying intellectually curious and the path to commercialization continued
46:11	Hitting Series A milestones with less than $500K of the original $5M raised in seed round
49:34	Lessons learned as a solo founder

Transcript

Clip

Loading transcript...